Answers are grounded in this paper and cite their sources.
Objectives: The study was aimed to investigate the relationship between plasma transforming growth factor beta 1 (TGF-β₁) expression and the characteristics of hepatocellular carcinoma (HCC). Methods: Five hundred and seventy-one patients with HCC were subjected. Plasma TGF-β₁ levels were measured by enzyme-linked immunosorbent assay at diagnosis and compared in accordance with clinical and radiological characteristics. Results: Plasma TGF-β₁ levels were significantly higher in the diffuse infiltrative type (n = 159) than in the nodular type of HCC (n = 412; 3.94 ± 0.34 vs. 3.79 ± 0.29 log₁₀ pg/ml; p < 0.001). They were much higher in patients with portal vein thrombosis or extrahepatic metastasis than in those without (3.88 ± 0.34 vs. 3.81 ± 0.29 log₁₀ pg/ml, p = 0.008; 3.94 ± 0.35 vs. 3.82 ± 0.30 log₁₀ pg/ml, p = 0.013, respectively). Also, plasma TGF-β₁ levels showed a positive correlation with the size of HCC (r = 0.014, p < 0.001). Additionally, plasma TGF-β₁ levels were inversely related to the survival periods (p < 0.001). Conclusion: TGF-β₁ was overexpressed in invasive types of HCC and it may be involved in the rapid progression of HCC.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: